Uses

Used in the treatment of metastatic colorectal cancer, either alone or in combination chemotherapy regimens.

Do not use if

Contraindicated in patients with hypersensitivity to irinotecan or formulation components.

May cause severe diarrhea, neutropenia, nausea, vomiting, alopecia, anemia, and fatigue.

Severe diarrhea and myelosuppression may be life-threatening and require close monitoring.

Irinotecan is a topoisomerase I inhibitor whose active metabolite interferes with DNA replication in cancer cells.

Store at 20–25°C and protect from light.